Mark Wiggins

A member of our board of directors since May 2011, Mr. Wiggins has expertise in business development activities and the marketing of pharmaceutical products, as well as management experience within the biopharmaceutical industry. Mr. Wiggins is currently the Chief Business Officer at Tracon Pharmaceuticals, a mid-stage oncology biotech company. Until 2015 Mr. Wiggins was Senior Vice President of Business Development with Elcelyx Therapeutics, Inc. Previously, he served as Chief Business Officer with Mpex Pharmaceuticals until its acquisition by Axcan in 2011. From May 1998 to February 2009, Mr. Wiggins was employed at Biogen Idec, Inc., and its predecessor Idec Pharmaceuticals, Corp., biotechnology companies, where he most recently served as Executive Vice President of Corporate and Business Development. At Idec Pharmaceuticals, Mr. Wiggins led Marketing and Business Development and was a member of the management committee for the corporate collaboration with Genentech on Rituxan®. Prior to Biogen Idec, Mr. Wiggins spent fifteen years in a number of positions of increasing responsibility in marketing, marketing research and business development at Hybridon, Inc., Schering-Plough Corporation (now Merck), Johnson & Johnson and Pfizer, Inc. Mr. Wiggins’ business development transaction experience includes closing over twenty licensing deals and several global corporate partnerships and company acquisitions. Mr. Wiggins earned his B.S. degree in Finance from Syracuse University and an M.B.A. from the University of Arizona.